Subject(s)
Clinical Trials as Topic , Coronavirus Infections/prevention & control , Drug Approval/legislation & jurisprudence , Drug Industry , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Politics , Research Personnel , Safety , Viral Vaccines/adverse effects , COVID-19 , COVID-19 Vaccines , Clinical Trial Protocols as Topic , Clinical Trials as Topic/ethics , Clinical Trials as Topic/methods , Clinical Trials as Topic/standards , Coronavirus Infections/epidemiology , Disclosure , Drug Industry/ethics , Drug Industry/legislation & jurisprudence , Drug Industry/standards , Humans , Myelitis, Transverse/etiology , Pneumonia, Viral/epidemiology , Public Opinion , Research Personnel/psychology , Sample Size , United Kingdom , United States , United States Food and Drug Administration/legislation & jurisprudence , Viral Vaccines/standardsABSTRACT
Later that year, she and four other women with the condition founded the Patient-Led Research Collaborative, a group of researchers who conduct and inform studies into the condition. The collaborative's approach feels particularly fitting for long COVID: from the start, patients have often had to advocate for their own medical care and design their own treatment regimens. "What they've been able to do in such a short period of time has been outstanding," says Kelly O'Brien, a physical therapist at the University of Toronto in Canada, who has collaborated with the group on a study about symptom fluctuations.
Subject(s)
Betacoronavirus/pathogenicity , Clinical Decision-Making , Coronavirus Infections/drug therapy , Coronavirus Infections/immunology , Interleukin-6/antagonists & inhibitors , Pneumonia, Viral/drug therapy , Pneumonia, Viral/immunology , Steroids/adverse effects , Steroids/therapeutic use , Uncertainty , Antibodies, Monoclonal, Humanized/pharmacology , Antibodies, Monoclonal, Humanized/therapeutic use , Betacoronavirus/drug effects , Betacoronavirus/immunology , COVID-19 , Coronavirus Infections/mortality , Coronavirus Infections/pathology , Humans , Immunosuppressive Agents/pharmacology , Immunosuppressive Agents/therapeutic use , Interleukin-6/immunology , Macrophages/drug effects , Macrophages/immunology , Pandemics , Physicians/psychology , Pneumonia, Viral/mortality , Pneumonia, Viral/pathology , Randomized Controlled Trials as Topic , SARS-CoV-2 , Steroids/administration & dosage , Steroids/pharmacology , T-Lymphocytes/drug effects , T-Lymphocytes/immunologyABSTRACT
Dracula was an immigrant bearing a disease that polluted the blood of London residents;Arthur Conan Doyle might have been one of the first to recognize the spectre of drug resistance in tuberculosis, while researching a newspaper article. Better antibiotics to treat drugresistant tuberculosis in India are expensive and in limited supply. [...]2019, they were strictly rationed and available only to people who fitted a specific disease profile and lived near one of a handful of hospitals. Only chapters later does she clearly lay out a key rationale for this restricted access: that researchers were still conducting trials to evaluate the drug's possible toxic effects on the heart.